Hemab Therapeutics Holdings, Inc. is a clinical-stage biotechnology company dedicated to transforming the treatment landscape for patients with serious bleeding and thrombotic disorders. The company leverages its deep expertise in blood clotting biology to develop a pipeline of first-in-class prophylactic therapies. Hemab's strategic focus is on addressing rare and underserved hematological conditions where current treatment options are limited or non-existent. The company's lead product candidate, HMB-001, is a bispecific antibody designed to bind and recruit Factor VIIa to activated platelets, specifically targeting Glanzmann Thrombasthenia, a severe rare bleeding disorder. Another key candidate in their pipeline is HMB-VWF, aimed at treating von Willebrand disease. By utilizing innovative engineering platforms, Hemab aims to provide long-acting, subcutaneous treatments that improve patient outcomes and quality of life. Founded by experts in the field of hematology and backed by prominent life science investors, Hemab operates with a dual presence in Denmark and the United States. The company is led by CEO Benny Sorensen, MD, PhD, who brings extensive experience in clinical development and hematology. Hemab's mission is to build a sustainable, fully integrated company that delivers life-changing medicines to patients globally, while advancing the science of hemostasis and thrombosis.
Market capitalization, or "market cap", is the aggregate market value of a company represented in a dollar amount. Since it represents the “market” value of a company, it is computed based on the current market price (CMP) of its shares and the total number of outstanding shares.
Enterprise value (EV) measures a company's total value, often used as a more comprehensive alternative to equity market capitalization. EV includes in its calculation the market capitalization of a company but also short-term and long-term debt and any cash or cash equivalents on the company's balance sheet.
The enterprise value-to-revenue multiple (EV/R) is a measure of the value of a stock that compares a company's enterprise value to its revenue. EV/R is one of several fundamental indicators that investors use to determine whether a stock is priced fairly. The EV/R multiple is also often used to determine a company's valuation in the case of a potential acquisition. It's also called the enterprise value-to-sales multiple.
The enterprise value to earnings before interest, taxes, depreciation, and amortization ratio (EV/EBITDA) compares the value of a company—debt included—to the company's cash earnings less non-cash expenses. It's best to use the EV/EBITDA metric when comparing companies within the same industry or sector. Typically, when evaluating a company, an EV/EBITDA value below 10 is seen as healthy.
It follows the same logic as the EV/EBITDA indicator, but instead of EBITDA, EBIT is used, which considers non-cash D&A expenses in the company's operating result.
...and much more!